;PMID: 11092558
;source_file_2919.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..108] = [t:43..108]
;2)section:[e:112..139] = [t:112..139]
;3)section:[e:143..268] = [t:143..268]
;4)sentence:[e:272..403] = [t:272..403]
;5)sentence:[e:404..581] = [t:404..581]
;6)sentence:[e:582..706] = [t:582..706]
;7)sentence:[e:707..781] = [t:707..781]
;8)sentence:[e:782..899] = [t:782..899]
;9)sentence:[e:900..1062] = [t:900..1062]
;10)sentence:[e:1063..1235] = [t:1063..1235]
;11)sentence:[e:1236..1421] = [t:1236..1421]
;12)section:[e:1425..1470] = [t:1425..1470]

;section 0 Span:0..37
;Mol Biol Rep.  2000 Jun;27(2):113-21.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..8] Biol) (NNP:[9..13] Rep.) (CD:[15..19] 2000)
        (CD:[20..26] Jun;27) (-LRB-:[26..27] -LRB-) (CD:[27..28] 2)
        (-RRB-:[28..29] -RRB-) (::[29..30] :) (NN:[30..34] 113-)
        (CD:[34..36] 21) (.:[36..37] .)))

;sentence 1 Span:43..108
;Efficient DNA transfection in neuronal and astrocytic cell lines.
(SENT
  (NP-HLN
    (NP (JJ:[43..52] Efficient) (NN:[53..56] DNA) (NN:[57..69] transfection))
    (PP (IN:[70..72] in)
      (NP
        (NP (JJ:[73..81] neuronal)
          (NML-1 (-NONE-:[81..81] *P*)))
        (CC:[82..85] and)
        (NP (JJ:[86..96] astrocytic)
          (NML-1 (NN:[97..101] cell) (NNS:[102..107] lines)))))
    (.:[107..108] .)))

;section 2 Span:112..139
;Ghosh C, Song W, Lahiri DK.
(SEC
  (FRAG (NNP:[112..117] Ghosh) (NNP:[118..119] C) (,:[119..120] ,)
        (NNP:[121..125] Song) (NNP:[126..127] W) (,:[127..128] ,)
        (NNP:[129..135] Lahiri) (NNP:[136..139] DK.)))

;section 3 Span:143..268
;Institute of Psychiatric Research, Department of Psychiatry, Indiana
;University  School of Medicine, Indianapolis 46202, USA.
(SEC
  (FRAG (NNP:[143..152] Institute) (IN:[153..155] of)
        (NNP:[156..167] Psychiatric) (NNP:[168..176] Research) (,:[176..177] ,)
        (NNP:[178..188] Department) (IN:[189..191] of)
        (NNP:[192..202] Psychiatry) (,:[202..203] ,) (NNP:[204..211] Indiana)
        (NNP:[212..222] University) (NNP:[224..230] School) (IN:[231..233] of)
        (NNP:[234..242] Medicine) (,:[242..243] ,) (NNP:[244..256] Indianapolis)
        (CD:[257..262] 46202) (,:[262..263] ,) (NNP:[264..267] USA)
        (.:[267..268] .)))

;sentence 4 Span:272..403
;We have studied different parameters for efficient DNA transfection in
;various  cell types and with different size of the promoter.
(SENT
  (S
    (NP-SBJ (PRP:[272..274] We))
    (VP (VBP:[275..279] have)
      (VP (VBN:[280..287] studied)
        (NP
          (NP (JJ:[288..297] different) (NNS:[298..308] parameters))
          (PP (IN:[309..312] for)
            (NP (JJ:[313..322] efficient) (NN:[323..326] DNA)
                (NN:[327..339] transfection))))
        (PP
          (PP-LOC (IN:[340..342] in)
            (NP (JJ:[343..350] various) (NN:[352..356] cell)
                (NNS:[357..362] types)))
          (CC:[363..366] and)
          (PP (IN:[367..371] with)
            (NP
              (NP (JJ:[372..381] different) (NN:[382..386] size))
              (PP (IN:[387..389] of)
                (NP (DT:[390..393] the) (NN:[394..402] promoter))))))))
    (.:[402..403] .)))

;sentence 5 Span:404..581
;Here we report that the  optimum condition for DNA transfection by
;electroporation is 350 V/960 microF  for PC12, 450V/960 microF C6 cells, and
;250 V/500 microF for COS-1 cells.
(SENT
  (S
    (ADVP (RB:[404..408] Here))
    (NP-SBJ (PRP:[409..411] we))
    (VP (VBP:[412..418] report)
      (SBAR (IN:[419..423] that)
        (S
          (NP-SBJ
            (NP (DT:[424..427] the) (JJ:[429..436] optimum)
                (NN:[437..446] condition))
            (PP (IN:[447..450] for)
              (NP
                (NP (NN:[451..454] DNA) (NN:[455..467] transfection))
                (PP (IN:[468..470] by)
                  (NP (NN:[471..486] electroporation))))))
          (VP
            (VP (VBZ:[487..489] is)
              (NP-PRD=1
                (NP (CD:[490..493] 350) (NN:[494..495] V))
                (PP (SYM:[495..496] /)
                  (NP (CD:[496..499] 960) (NN:[500..506] microF))))
              (PP=2 (IN:[508..511] for)
                (NP=3 (NN:[512..516] PC12))))
            (,:[516..517] ,)
            (VP
              (NP-PRD=1
                (NP (CD:[518..521] 450) (NN:[521..522] V))
                (PP (SYM:[522..523] /)
                  (NP (CD:[523..526] 960) (NN:[527..533] microF))))
              (NP=3 (NN:[534..536] C6) (NNS:[537..542] cells)))
            (,:[542..543] ,) (CC:[544..547] and)
            (VP
              (NP-PRD=1
                (NP (CD:[548..551] 250) (NN:[552..553] V))
                (PP (SYM:[553..554] /)
                  (NP (CD:[554..557] 500) (NN:[558..564] microF))))
              (PP=2 (IN:[565..568] for)
                (NP (NN:[569..574] COS-1) (NNS:[575..580] cells))))))))
    (.:[580..581] .)))

;sentence 6 Span:582..706
;For  the human neuroblastoma (SK-N-SH) cells the optimum condition for DNA 
;transfection is by the calcium phosphate method.
;[597..610]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (PP (IN:[582..585] For)
      (NP (DT:[587..590] the)
        (NML
          (NML (JJ:[591..596] human) (NN:[597..610] neuroblastoma))
          (NML (-LRB-:[611..612] -LRB-) (NN:[612..619] SK-N-SH)
               (-RRB-:[619..620] -RRB-)))
        (NNS:[621..626] cells)))
    (NP-SBJ
      (NP (DT:[627..630] the) (JJ:[631..638] optimum) (NN:[639..648] condition))
      (PP (IN:[649..652] for)
        (NP (NN:[653..656] DNA) (NN:[658..670] transfection))))
    (VP (VBZ:[671..673] is)
      (PP-PRD (IN:[674..676] by)
        (NP (DT:[677..680] the)
          (NML (NN:[681..688] calcium) (NN:[689..698] phosphate))
          (NN:[699..705] method))))
    (.:[705..706] .)))

;sentence 7 Span:707..781
;In promoter mapping studies, a  serial deletion approach is commonly used.
(SENT
  (S
    (PP (IN:[707..709] In)
      (NP
        (NML (NN:[710..718] promoter) (NN:[719..726] mapping))
        (NNS:[727..734] studies)))
    (,:[734..735] ,)
    (NP-SBJ-1 (DT:[736..737] a)
      (NML (JJ:[739..745] serial) (NN:[746..754] deletion))
      (NN:[755..763] approach))
    (VP (VBZ:[764..766] is)
      (ADVP (RB:[767..775] commonly))
      (VP (VBN:[776..780] used)
        (NP-1 (-NONE-:[780..780] *))))
    (.:[780..781] .)))

;sentence 8 Span:782..899
;To optimize transfection we have  selected three DNA constructs that varied
;in size from 4.5 to 12.4 kilobases  (kb).
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[782..782] *))
      (VP (TO:[782..784] To)
        (VP (VB:[785..793] optimize)
          (NP (NN:[794..806] transfection)))))
    (NP-SBJ (PRP:[807..809] we))
    (VP (VBP:[810..814] have)
      (VP (VBN:[816..824] selected)
        (NP
          (NP (CD:[825..830] three) (NN:[831..834] DNA)
              (NNS:[835..845] constructs))
          (SBAR
            (WHNP-1 (WDT:[846..850] that))
            (S
              (NP-SBJ-1 (-NONE-:[850..850] *T*))
              (VP (VBD:[851..857] varied)
                (PP (IN:[858..860] in)
                  (NP (NN:[861..865] size)))
                (PP
                  (PP (IN:[866..870] from)
                    (NP (CD:[871..874] 4.5)
                      (NML-2 (-NONE-:[874..874] *RNR*))))
                  (PP (TO:[875..877] to)
                    (NP (CD:[878..882] 12.4)
                      (NML-2 (-NONE-:[882..882] *RNR*))))
                  (NML-2
                    (NML (NNS:[883..892] kilobases))
                    (NML (-LRB-:[894..895] -LRB-) (NN:[895..897] kb)
                         (-RRB-:[897..898] -RRB-))))))))))
    (.:[898..899] .)))

;sentence 9 Span:900..1062
;We measured the promoter activity of these constructs under conditions of 
;'equal amount', 'equimolar', and 'equimolar plus carrier DNA to make it equal
; amount'.
(SENT
  (S
    (NP-SBJ (PRP:[900..902] We))
    (VP (VBD:[903..911] measured)
      (NP
        (NP (DT:[912..915] the) (NN:[916..924] promoter)
            (NN:[925..933] activity))
        (PP (IN:[934..936] of)
          (NP (DT:[937..942] these) (NNS:[943..953] constructs))))
      (PP (IN:[954..959] under)
        (NP
          (NP (NNS:[960..970] conditions))
          (PP (IN:[971..973] of)
            (UCP
              (NP (``:[975..976] ') (JJ:[976..981] equal) (NN:[982..988] amount)
                  ('':[988..989] '))
              (,:[989..990] ,)
              (ADJP (``:[991..992] ') (JJ:[992..1001] equimolar)
                    ('':[1001..1002] '))
              (,:[1002..1003] ,) (CC:[1004..1007] and)
              (FRAG (``:[1008..1009] ')
                (NP
                  (NP (JJ:[1009..1018] equimolar))
                  (CC:[1019..1023] plus)
                  (NP (NN:[1024..1031] carrier) (NN:[1032..1035] DNA)))
                (S-PRP
                  (NP-SBJ (-NONE-:[1035..1035] *))
                  (VP (TO:[1036..1038] to)
                    (VP (VB:[1039..1043] make)
                      (S
                        (NP-SBJ (PRP:[1044..1046] it))
                        (NP-PRD (JJ:[1047..1052] equal) (NN:[1054..1060] amount))))))
                ('':[1060..1061] ')))))))
    (.:[1061..1062] .)))

;sentence 10 Span:1063..1235
;We recommend that for comparative purpose, transfection should be  carried
;out under 'equimolar condition' without a need to adjust the total  amount of
;DNA by carrier DNA.
(SENT
  (S
    (NP-SBJ (PRP:[1063..1065] We))
    (VP (VBP:[1066..1075] recommend)
      (SBAR (IN:[1076..1080] that)
        (S
          (PP (IN:[1081..1084] for)
            (NP (JJ:[1085..1096] comparative) (NN:[1097..1104] purpose)))
          (,:[1104..1105] ,)
          (NP-SBJ-1 (NN:[1106..1118] transfection))
          (VP (MD:[1119..1125] should)
            (VP (VB:[1126..1128] be)
              (VP (VBN:[1130..1137] carried)
                (PRT (RP:[1138..1141] out))
                (NP-1 (-NONE-:[1141..1141] *))
                (PP (IN:[1142..1147] under)
                  (NP (``:[1148..1149] ') (JJ:[1149..1158] equimolar)
                      (NN:[1159..1168] condition) ('':[1168..1169] ')))
                (PP (IN:[1170..1177] without)
                  (NP (DT:[1178..1179] a) (NN:[1180..1184] need)
                    (S
                      (NP-SBJ (-NONE-:[1184..1184] *))
                      (VP (TO:[1185..1187] to)
                        (VP (VB:[1188..1194] adjust)
                          (NP
                            (NP (DT:[1195..1198] the) (JJ:[1199..1204] total)
                                (NN:[1206..1212] amount))
                            (PP (IN:[1213..1215] of)
                              (NP (NN:[1216..1219] DNA))))
                          (PP-MNR (IN:[1220..1222] by)
                            (NP (NN:[1223..1230] carrier) (NN:[1231..1234] DNA))))))))))))))
    (.:[1234..1235] .)))

;sentence 11 Span:1236..1421
;Taken together, our results suggest that efficient  methods for DNA
;transfection are important to study gene regulation by devising  better ways
;to deliver DNA into the mammalian cells.
(SENT
  (S
    (S-ADV
      (NP-SBJ-1 (-NONE-:[1236..1236] *))
      (VP (VBN:[1236..1241] Taken)
        (NP-1 (-NONE-:[1241..1241] *))
        (ADVP (RB:[1242..1250] together))))
    (,:[1250..1251] ,)
    (NP-SBJ (PRP$:[1252..1255] our) (NNS:[1256..1263] results))
    (VP (VBP:[1264..1271] suggest)
      (SBAR (IN:[1272..1276] that)
        (S
          (NP-SBJ
            (NP (JJ:[1277..1286] efficient) (NNS:[1288..1295] methods))
            (PP (IN:[1296..1299] for)
              (NP (NN:[1300..1303] DNA) (NN:[1304..1316] transfection))))
          (VP (VBP:[1317..1320] are)
            (ADJP-PRD (JJ:[1321..1330] important))
            (S-PRP
              (NP-SBJ (-NONE-:[1330..1330] *))
              (VP (TO:[1331..1333] to)
                (VP (VB:[1334..1339] study)
                  (NP (NN:[1340..1344] gene) (NN:[1345..1355] regulation))
                  (PP-MNR (IN:[1356..1358] by)
                    (S-NOM
                      (NP-SBJ (-NONE-:[1358..1358] *))
                      (VP (VBG:[1359..1367] devising)
                        (NP (JJR:[1369..1375] better) (NNS:[1376..1380] ways)
                          (S
                            (NP-SBJ (-NONE-:[1380..1380] *))
                            (VP (TO:[1381..1383] to)
                              (VP (VB:[1384..1391] deliver)
                                (NP (NN:[1392..1395] DNA))
                                (PP-DIR (IN:[1396..1400] into)
                                  (NP (DT:[1401..1404] the)
                                      (JJ:[1405..1414] mammalian)
                                      (NNS:[1415..1420] cells)))))))))))))))))
    (.:[1420..1421] .)))

;section 12 Span:1425..1470
;PMID: 11092558 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1425..1429] PMID) (::[1429..1430] :) (CD:[1431..1439] 11092558)
        (NN:[1440..1441] -LSB-) (NNP:[1441..1447] PubMed) (::[1448..1449] -)
        (NN:[1450..1457] indexed) (IN:[1458..1461] for)
        (NNP:[1462..1470] MEDLINE-RSB-)))
